Dr. Evan C. Chen, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Stanford University School of Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 93
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Stanford University School of Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 278136
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- North Shore Medical Center - Salem, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 93
- Services billed
- 322
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 174 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 93 | 28 |
| Established patient office or other outpatient visit, 40-54 minutes | 35 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Hospital discharge day management, 30 minutes or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Boston, MA | 22 |
| Allopurinol Other prescribers in Boston, MA | 21 |
| Venclexta (venetoclax) | 20 |
| Hydroxyurea Other prescribers in Boston, MA | 16 |
| Levofloxacin Other prescribers in Boston, MA | 14 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 13 |
| Chlorhexidine Gluconate Other prescribers in Boston, MA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 21 payments worth $20,716 in total to this clinician.
| Merck Sharp & Dohme LLC | $10,102 |
|---|---|
| Syndax Pharmaceuticals, Inc. | $6,211 |
| Autolus Inc | $3,719 |
| Rigel Pharmaceuticals, Inc. | $685 |
| Consulting Fee | $14,902 |
|---|---|
| Honoraria | $3,545 |
| Travel and Lodging | $1,527 |
| Food and Beverage | $743 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. May 3, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $4,800 |
| Merck Sharp & Dohme LLC Mar 26, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $3,965 |
| Autolus Inc Dec 5, 2025 | Honoraria in-kind | $2,860 |
| Merck Sharp & Dohme LLC Oct 29, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $1,586 |
| Merck Sharp & Dohme LLC Aug 18, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,403 |
| Merck Sharp & Dohme LLC Jul 2, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $1,135 |
| Merck Sharp & Dohme LLC Jun 4, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $915 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $793 |
| Rigel Pharmaceuticals, Inc. Sep 5, 2025 | Honoraria Rezlidhia · Acute Myeloid Leukemia | $685 |
| Syndax Pharmaceuticals, Inc. May 3, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind | $591 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Autolus Inc Dec 5, 2025 | Honoraria in-kind | $2,860 |
| Autolus Inc Dec 5, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $341 |
| Autolus Inc Dec 5, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $300 |
| Merck Sharp & Dohme LLC Oct 29, 2025 | Consulting Fee WINREVAIR · CARDIOVASCULAR Company’s descriptionProvided as part of a clinical research engagement. | $1,586 |
| Rigel Pharmaceuticals, Inc. Sep 5, 2025 | Honoraria Rezlidhia · Acute Myeloid Leukemia | $685 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $793 |
| Merck Sharp & Dohme LLC Aug 18, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,403 |
| Merck Sharp & Dohme LLC Aug 13, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $305 |
| Merck Sharp & Dohme LLC Jul 2, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $1,135 |
| Merck Sharp & Dohme LLC Jun 4, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $915 |
| Syndax Pharmaceuticals, Inc. May 3, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $4,800 |
| Syndax Pharmaceuticals, Inc. May 3, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind | $591 |
| Syndax Pharmaceuticals, Inc. May 3, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind | $184 |
| Syndax Pharmaceuticals, Inc. May 3, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind | $79.83 |
| Syndax Pharmaceuticals, Inc. May 3, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL | $32.00 |
| Merck Sharp & Dohme LLC Mar 26, 2025 | Consulting FeeCompany’s descriptionProvided as part of a clinical research engagement. | $3,965 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $51,634 in research payments for these studies, mostly to the institutions running them.
- TAK-012-1501
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.